JP2018512430A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512430A5 JP2018512430A5 JP2017553118A JP2017553118A JP2018512430A5 JP 2018512430 A5 JP2018512430 A5 JP 2018512430A5 JP 2017553118 A JP2017553118 A JP 2017553118A JP 2017553118 A JP2017553118 A JP 2017553118A JP 2018512430 A5 JP2018512430 A5 JP 2018512430A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- sequence
- cancer
- csf1r
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 26
- 230000003308 immunostimulating effect Effects 0.000 claims 20
- 239000003814 drug Substances 0.000 claims 16
- 239000000556 agonist Substances 0.000 claims 15
- -1 CEACAM-1 Proteins 0.000 claims 12
- 108010029697 CD40 Ligand Proteins 0.000 claims 6
- 102100032937 CD40 ligand Human genes 0.000 claims 6
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 6
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 6
- 102100034980 ICOS ligand Human genes 0.000 claims 6
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 6
- 108010082808 4-1BB Ligand Proteins 0.000 claims 4
- 102100038078 CD276 antigen Human genes 0.000 claims 4
- 101710185679 CD276 antigen Proteins 0.000 claims 4
- 101150013553 CD40 gene Proteins 0.000 claims 4
- 102100025221 CD70 antigen Human genes 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 4
- 102100037354 Ectodysplasin-A Human genes 0.000 claims 4
- 101000880080 Homo sapiens Ectodysplasin-A Proteins 0.000 claims 4
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims 4
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 claims 4
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims 4
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 4
- 102000003814 Interleukin-10 Human genes 0.000 claims 4
- 108090000174 Interleukin-10 Proteins 0.000 claims 4
- 102000013462 Interleukin-12 Human genes 0.000 claims 4
- 108010065805 Interleukin-12 Proteins 0.000 claims 4
- 102000003812 Interleukin-15 Human genes 0.000 claims 4
- 108090000172 Interleukin-15 Proteins 0.000 claims 4
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 102000000588 Interleukin-2 Human genes 0.000 claims 4
- 108090001005 Interleukin-6 Proteins 0.000 claims 4
- 102000004889 Interleukin-6 Human genes 0.000 claims 4
- 102100021592 Interleukin-7 Human genes 0.000 claims 4
- 108010002586 Interleukin-7 Proteins 0.000 claims 4
- 102000017578 LAG3 Human genes 0.000 claims 4
- 101150030213 Lag3 gene Proteins 0.000 claims 4
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 4
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 102000004473 OX40 Ligand Human genes 0.000 claims 4
- 108010042215 OX40 Ligand Proteins 0.000 claims 4
- 230000006044 T cell activation Effects 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 4
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 claims 4
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 4
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims 4
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 4
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 4
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 4
- 230000000139 costimulatory effect Effects 0.000 claims 4
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 4
- 108010074108 interleukin-21 Proteins 0.000 claims 4
- 210000000822 natural killer cell Anatomy 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 2
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 claims 2
- 102000007471 Adenosine A2A receptor Human genes 0.000 claims 2
- 108010085277 Adenosine A2A receptor Proteins 0.000 claims 2
- 102100031934 Adhesion G-protein coupled receptor G1 Human genes 0.000 claims 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 2
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 claims 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 2
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 2
- 108010046080 CD27 Ligand Proteins 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 2
- 229940123189 CD40 agonist Drugs 0.000 claims 2
- 102100036008 CD48 antigen Human genes 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 2
- 108010012236 Chemokines Proteins 0.000 claims 2
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 claims 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 2
- 101150089023 FASLG gene Proteins 0.000 claims 2
- 102000000795 Galectin 1 Human genes 0.000 claims 2
- 108010001498 Galectin 1 Proteins 0.000 claims 2
- 102100031351 Galectin-9 Human genes 0.000 claims 2
- 101710121810 Galectin-9 Proteins 0.000 claims 2
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 2
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 claims 2
- 101000775042 Homo sapiens Adhesion G-protein coupled receptor G1 Proteins 0.000 claims 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 2
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 2
- 101001068136 Homo sapiens Hepatitis A virus cellular receptor 1 Proteins 0.000 claims 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 2
- 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 claims 2
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims 2
- 101001023712 Homo sapiens Nectin-3 Proteins 0.000 claims 2
- 101000831286 Homo sapiens Protein timeless homolog Proteins 0.000 claims 2
- 101000752245 Homo sapiens Rho guanine nucleotide exchange factor 5 Proteins 0.000 claims 2
- 101000669511 Homo sapiens T-cell immunoglobulin and mucin domain-containing protein 4 Proteins 0.000 claims 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 2
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 claims 2
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims 2
- 101000764622 Homo sapiens Transmembrane and immunoglobulin domain-containing protein 2 Proteins 0.000 claims 2
- 101000610602 Homo sapiens Tumor necrosis factor receptor superfamily member 10C Proteins 0.000 claims 2
- 101000610609 Homo sapiens Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 claims 2
- 101000798130 Homo sapiens Tumor necrosis factor receptor superfamily member 11B Proteins 0.000 claims 2
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims 2
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 2
- 101000801227 Homo sapiens Tumor necrosis factor receptor superfamily member 19 Proteins 0.000 claims 2
- 101000679921 Homo sapiens Tumor necrosis factor receptor superfamily member 21 Proteins 0.000 claims 2
- 101000679907 Homo sapiens Tumor necrosis factor receptor superfamily member 27 Proteins 0.000 claims 2
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 101000920026 Homo sapiens Tumor necrosis factor receptor superfamily member EDAR Proteins 0.000 claims 2
- 101710093458 ICOS ligand Proteins 0.000 claims 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 2
- 102100030703 Interleukin-22 Human genes 0.000 claims 2
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims 2
- 102000002698 KIR Receptors Human genes 0.000 claims 2
- 108010043610 KIR Receptors Proteins 0.000 claims 2
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 claims 2
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 2
- 101100046559 Mus musculus Tnfrsf12a gene Proteins 0.000 claims 2
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 claims 2
- 102100035487 Nectin-3 Human genes 0.000 claims 2
- 108091007960 PI3Ks Proteins 0.000 claims 2
- 102000014128 RANK Ligand Human genes 0.000 claims 2
- 108010025832 RANK Ligand Proteins 0.000 claims 2
- 108010052562 RELT Proteins 0.000 claims 2
- 102000018795 RELT Human genes 0.000 claims 2
- 102100039367 T-cell immunoglobulin and mucin domain-containing protein 4 Human genes 0.000 claims 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 2
- 108010014401 TWEAK Receptor Proteins 0.000 claims 2
- 102000016946 TWEAK Receptor Human genes 0.000 claims 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims 2
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 claims 2
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 claims 2
- 102100026224 Transmembrane and immunoglobulin domain-containing protein 2 Human genes 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 claims 2
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 claims 2
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 claims 2
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 claims 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims 2
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 claims 2
- 102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 claims 2
- 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 claims 2
- 102100032236 Tumor necrosis factor receptor superfamily member 11B Human genes 0.000 claims 2
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims 2
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 2
- 102100033760 Tumor necrosis factor receptor superfamily member 19 Human genes 0.000 claims 2
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims 2
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims 2
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims 2
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims 2
- 102100022205 Tumor necrosis factor receptor superfamily member 21 Human genes 0.000 claims 2
- 102100022202 Tumor necrosis factor receptor superfamily member 27 Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 102100030810 Tumor necrosis factor receptor superfamily member EDAR Human genes 0.000 claims 2
- 108040004564 crotonyl-CoA reductase activity proteins Proteins 0.000 claims 2
- 229950007409 dacetuzumab Drugs 0.000 claims 2
- 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 claims 2
- 102000052833 human CSF1R Human genes 0.000 claims 2
- 230000001506 immunosuppresive effect Effects 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 239000003970 toll like receptor agonist Substances 0.000 claims 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108091011896 CSF1 Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562146766P | 2015-04-13 | 2015-04-13 | |
| US62/146,766 | 2015-04-13 | ||
| US201562190945P | 2015-07-10 | 2015-07-10 | |
| US62/190,945 | 2015-07-10 | ||
| PCT/US2016/027038 WO2016168149A1 (en) | 2015-04-13 | 2016-04-12 | Combination therapy for cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512430A JP2018512430A (ja) | 2018-05-17 |
| JP2018512430A5 true JP2018512430A5 (enExample) | 2019-05-23 |
| JP6971850B2 JP6971850B2 (ja) | 2021-11-24 |
Family
ID=55809223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017553118A Active JP6971850B2 (ja) | 2015-04-13 | 2016-04-12 | がんの併用療法 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20180085472A1 (enExample) |
| EP (2) | EP3964527A3 (enExample) |
| JP (1) | JP6971850B2 (enExample) |
| KR (1) | KR20170135924A (enExample) |
| CN (2) | CN114681608A (enExample) |
| AU (1) | AU2016249981B2 (enExample) |
| BR (1) | BR112017020952A2 (enExample) |
| CA (1) | CA2980460A1 (enExample) |
| CY (1) | CY1123972T1 (enExample) |
| DK (1) | DK3283527T3 (enExample) |
| ES (1) | ES2857076T3 (enExample) |
| HU (1) | HUE053903T2 (enExample) |
| IL (1) | IL254705B (enExample) |
| LT (1) | LT3283527T (enExample) |
| MX (1) | MX388015B (enExample) |
| PL (1) | PL3283527T3 (enExample) |
| PT (1) | PT3283527T (enExample) |
| RS (1) | RS61531B1 (enExample) |
| SI (1) | SI3283527T1 (enExample) |
| SM (1) | SMT202100132T1 (enExample) |
| TW (1) | TWI725966B (enExample) |
| WO (1) | WO2016168149A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016251687C1 (en) | 2015-04-22 | 2023-07-27 | CureVac SE | RNA containing composition for treatment of tumor diseases |
| EP3294885B1 (en) | 2015-05-08 | 2020-07-01 | CureVac Real Estate GmbH | Method for producing rna |
| JP6621252B2 (ja) * | 2015-06-17 | 2019-12-18 | 国立大学法人北海道大学 | 治療耐性がんに対する治療耐性低減剤 |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
| WO2018144334A1 (en) * | 2017-02-02 | 2018-08-09 | Imclone Llc | Dosing regimen for anti-csf-1r antibody |
| CN110381974A (zh) * | 2017-02-27 | 2019-10-25 | 沙塔克实验室有限公司 | 基于csf1r的嵌合蛋白 |
| WO2018160917A1 (en) * | 2017-03-03 | 2018-09-07 | Janssen Biotech, Inc. | Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer |
| WO2018183366A1 (en) * | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy |
| WO2018183608A1 (en) * | 2017-03-31 | 2018-10-04 | Five Prime Therapeutics, Inc. | Combination therapy for cancer using anti-gitr antibodies |
| AU2018256406A1 (en) * | 2017-04-19 | 2019-10-17 | Marengo Therapeutics, Inc. | Multispecific molecules and uses thereof |
| CN110267989B (zh) * | 2017-06-01 | 2023-04-04 | 江苏恒瑞医药股份有限公司 | 抗cd40抗体、其抗原结合片段及其医药用途 |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| AU2019302454A1 (en) * | 2018-07-09 | 2021-02-25 | Bristol-Myers Squibb Company | Antibodies binding to ILT4 |
| EP3833762A4 (en) | 2018-08-09 | 2022-09-28 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
| CN113164777B (zh) * | 2018-09-27 | 2024-12-13 | 马伦戈治疗公司 | Csf1r/ccr2多特异性抗体 |
| CN109364252B (zh) * | 2018-11-21 | 2021-09-28 | 南京大学 | 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用 |
| JP2022509156A (ja) * | 2018-11-30 | 2022-01-20 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 |
| CN112839961B (zh) * | 2018-11-30 | 2023-04-04 | 江苏恒瑞医药股份有限公司 | 一种cd40抗体药物组合物及其用途 |
| EP3927747A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| CN119661722A (zh) | 2019-02-21 | 2025-03-21 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| WO2020178313A1 (en) * | 2019-03-05 | 2020-09-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New biomarkers and biotargets in renal cell carcinoma |
| CA3136491A1 (en) * | 2019-04-10 | 2020-10-15 | Nankai University | Anti-cd40 antibodies and uses thereof |
| TW202112812A (zh) * | 2019-05-24 | 2021-04-01 | 香港商安立璽榮生醫(香港)有限公司 | Csf1r抗體、il10融合蛋白及其用途 |
| CN110904229B (zh) * | 2019-11-25 | 2020-09-29 | 济南市中心医院 | Ilt4在肿瘤诊治中的应用 |
| GB2609554B (en) | 2020-01-03 | 2025-08-20 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| WO2021142573A1 (zh) * | 2020-01-13 | 2021-07-22 | 丁邦 | 一种融合蛋白及其制法和用途 |
| TW202216768A (zh) | 2020-06-22 | 2022-05-01 | 美商恩格姆生物製藥公司 | Ｌａｉｒ－１結合劑及其使用方法 |
| AU2021391969A1 (en) * | 2020-12-04 | 2023-07-06 | Universitair Ziekenhuis Antwerpen | Combination immunotherapy of il-15 and cd40 agonist in cancer treatment |
| CN112979749A (zh) * | 2021-02-26 | 2021-06-18 | 深圳海创生物科技有限公司 | 一种活性环肽、活性环肽组合物及其在制备具有抗氧化作用或抗衰老作用的产品中的应用 |
| KR20240004462A (ko) | 2021-04-08 | 2024-01-11 | 마렝고 테라퓨틱스, 인크. | Tcr에 결합하는 다기능성 분자 및 이의 용도 |
| WO2024073111A2 (en) * | 2022-09-30 | 2024-04-04 | Adicet Therapeutics, Inc. | Affinity binding entities directed to b7h6 and methods of use thereof |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO1989003687A1 (en) | 1987-10-23 | 1989-05-05 | Genetics Institute, Inc. | Composition and method for treating cancers characterized by over-expression of the c-fms proto-oncogene |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| JPH08507916A (ja) | 1992-06-09 | 1996-08-27 | カイロン コーポレイション | Ｍ−ｃｓｆの結晶化 |
| US20020193575A1 (en) | 1993-09-07 | 2002-12-19 | Smithkline Beecham P.L.C. | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
| US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| WO1999029345A1 (en) | 1997-12-05 | 1999-06-17 | La Jolla Institute For Experimental Medicine | Inhibition of tumor growth by macrophage intervention |
| EP1125584A4 (en) | 1998-10-30 | 2005-01-12 | Takeda Chemical Industries Ltd | PREPARATIONS CONTAINING BETACELLULIN PROTEIN |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| ATE240744T1 (de) | 1999-10-28 | 2003-06-15 | Hofbauer Reinhold | Verwendung von csf-1-inhibitoren |
| AU1759501A (en) | 1999-11-08 | 2001-06-06 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Method of treating a viral infection using antagonists of macrophage colony stimulating factor |
| US7108852B2 (en) | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| US7455836B2 (en) | 2000-05-08 | 2008-11-25 | The University Of Melbourne | Method of treatment and agents useful for same |
| US6773895B2 (en) | 2000-09-01 | 2004-08-10 | Boehringer Ingelheim Pharma Kg | Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases |
| US7247618B2 (en) | 2001-04-30 | 2007-07-24 | Tripathi Rajavashisth | Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling |
| IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| DE60332483D1 (de) | 2002-11-15 | 2010-06-17 | Novartis Vaccines & Diagnostic | Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust |
| US7807389B2 (en) | 2003-03-14 | 2010-10-05 | University Of Rochester | Methods and compositions related to joint inflammation diseases |
| JP4810427B2 (ja) | 2003-05-22 | 2011-11-09 | アボット・ラボラトリーズ | インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤 |
| HUE033349T2 (en) | 2003-10-22 | 2017-11-28 | Keck Graduate Inst | Procedures for the Synthesis of Heteromultimer Polypeptides in Yeast Using an Hagloid Mating Strategy |
| GB0325836D0 (en) | 2003-11-05 | 2003-12-10 | Celltech R&D Ltd | Biological products |
| JP2007524671A (ja) | 2004-01-21 | 2007-08-30 | カイロン コーポレイション | Ｍ−ｃｓｆムテインおよびその使用 |
| US20060286102A1 (en) | 2004-05-14 | 2006-12-21 | Pei Jin | Cell surface receptor isoforms and methods of identifying and using the same |
| US20070264277A1 (en) | 2004-07-22 | 2007-11-15 | Dirk Behrens | Compositions and Methods of Use for Mgd-Csf in Disease Treatment |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| WO2006076288A2 (en) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
| WO2006081430A2 (en) | 2005-01-27 | 2006-08-03 | Five Prime Therapeutics, Inc. | Leader sequences for directing secretion of polypeptides and methods for production thereof |
| ES2657443T3 (es) | 2005-03-25 | 2018-03-05 | Gitr, Inc. | Anticuerpos anti-GITR y usos de los mismos |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| AU2006244068B9 (en) | 2005-05-10 | 2012-10-25 | Incyte Holdings Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
| ATE485057T1 (de) | 2005-05-26 | 2010-11-15 | Seattle Genetics Inc | Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung |
| KR20080082628A (ko) * | 2005-11-10 | 2008-09-11 | 리셉터 바이오로직스 인크 | 수용체 및 리간드 이소형태의 제조 방법 |
| CA2634198C (en) | 2005-12-20 | 2014-06-03 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| WO2007075933A2 (en) * | 2005-12-21 | 2007-07-05 | Cell Signaling Technology, Inc. | Translocation and mutant csf1r kinase in human leukemia |
| AU2006342119B8 (en) | 2005-12-22 | 2013-05-09 | Novartis Ag | Soluble human M-CSF receptor and uses thereof |
| RU2470665C2 (ru) | 2006-01-05 | 2012-12-27 | Новартис Аг | Способы профилактики и лечения ракового метастаза и разрежения кости, связанного с раковым метастазом |
| US20090074711A1 (en) | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| JP5319532B2 (ja) | 2006-09-19 | 2013-10-16 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル |
| EA016527B1 (ru) * | 2006-10-23 | 2012-05-30 | ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК. | Триазолопиридазиновые модуляторы протеинкиназ |
| WO2008060610A2 (en) | 2006-11-17 | 2008-05-22 | Biogen Idec Ma Inc. | Systemic administration of colony stimulating factors to treat amyloid associated disorders |
| EP2069404B1 (en) | 2007-02-14 | 2011-01-05 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
| WO2008124858A2 (en) | 2007-04-11 | 2008-10-23 | F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. | Targeted receptor |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| WO2008150383A1 (en) | 2007-05-30 | 2008-12-11 | Albert Einstein College Of Medicine Of Yeshiva University | Csf-1r mutants |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| TWI595005B (zh) | 2007-08-21 | 2017-08-11 | 安健股份有限公司 | 人類ｃ－ｆｍｓ抗原結合蛋白質 |
| US7981415B2 (en) | 2007-09-07 | 2011-07-19 | Cisthera, Inc. | Humanized PAI-1 antibodies |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| EP2215482A2 (en) | 2007-10-31 | 2010-08-11 | Janssen Pharmaceutica N.V. | Biomarker for assessing response to fms treatment |
| CA2932121A1 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics Corporation | Ido inhibitors |
| WO2009075344A1 (ja) | 2007-12-12 | 2009-06-18 | Japan As Represented By Director General Of Agency Of National Cancer Center | M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用 |
| BRPI0821962A2 (pt) | 2008-01-03 | 2019-05-07 | Univ De La Mediterrannee Aix Marseille Ii | composições e métodos usados durante um tratamento anti-hiv |
| US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
| MX2010009894A (es) | 2008-03-14 | 2011-02-22 | Transgene Sa | Anticuerpo contra csf-1r. |
| WO2009120905A2 (en) * | 2008-03-26 | 2009-10-01 | Cellerant Therapeutics, Inc. | Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof |
| MX2010012064A (es) | 2008-05-05 | 2010-12-06 | Schering Corp | Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer. |
| EP2307050A4 (en) | 2008-07-04 | 2012-07-25 | Ono Pharmaceutical Co | USE OF A EFFECTIVENESS MARKER TO OPTIMIZE THE THERAPEUTIC EFFECTIVENESS OF AN ANTI-HUMAN PD-1 ANTIBODY ON CANCERS |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| US8080246B2 (en) | 2008-11-26 | 2011-12-20 | Five Prime Therapeutics, Inc. | Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules |
| US8183207B2 (en) | 2008-11-26 | 2012-05-22 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules |
| CA2772613C (en) | 2009-09-03 | 2020-03-10 | Schering Corporation | Anti-gitr antibodies |
| PL2949670T3 (pl) | 2009-12-10 | 2019-07-31 | F. Hoffmann-La Roche Ag | Przeciwciała wiążące się preferencyjnie z zewnątrzkomórkową domeną 4 ludzkiego CSF-1R i ich zastosowanie |
| US9150656B2 (en) | 2010-03-04 | 2015-10-06 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
| US9221910B2 (en) | 2010-03-05 | 2015-12-29 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| AR080698A1 (es) | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
| AU2011248083B2 (en) | 2010-05-04 | 2015-09-10 | Five Prime Therapeutics, Inc. | Antibodies that bind CSF1R |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| US9029315B2 (en) | 2010-11-11 | 2015-05-12 | The University Of Hong Kong | Soluble PD-1 variants, fusion constructs, and uses thereof |
| WO2012082573A1 (en) | 2010-12-13 | 2012-06-21 | Novartis Ag | Predictive methods and methods of treating arthritis using il-17 antagonists |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| GB201115280D0 (en) | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| JP6005751B2 (ja) | 2011-10-21 | 2016-10-12 | トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． | マクロファージの活性化の調節 |
| WO2013057290A1 (en) | 2011-10-21 | 2013-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A m-dc8+ monocyte depleting agent for the prevention or the treatment of a condition associated with a chronic hyperactivation of the immune system |
| AR090263A1 (es) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| HK1208233A1 (en) | 2012-05-11 | 2016-02-26 | 戊瑞治疗有限公司 | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| EP2890398A4 (en) | 2012-08-31 | 2016-03-09 | Five Prime Therapeutics Inc | METHODS OF TREATING DISEASES WITH ANTIBODIES THAT BIND COLONY STIMULATING FACTOR RECEIVER 1 (CSF1R) |
| EP3838316B1 (en) | 2013-07-11 | 2024-04-03 | Alexza Pharmaceuticals, Inc. | Drug delivery and drug cessation system |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| US9765147B2 (en) | 2014-10-29 | 2017-09-19 | Five Prime Therapeutics, Inc. | Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer |
-
2016
- 2016-04-12 LT LTEP16718802.8T patent/LT3283527T/lt unknown
- 2016-04-12 PT PT167188028T patent/PT3283527T/pt unknown
- 2016-04-12 CA CA2980460A patent/CA2980460A1/en active Pending
- 2016-04-12 ES ES16718802T patent/ES2857076T3/es active Active
- 2016-04-12 SM SM20210132T patent/SMT202100132T1/it unknown
- 2016-04-12 HU HUE16718802A patent/HUE053903T2/hu unknown
- 2016-04-12 KR KR1020177032288A patent/KR20170135924A/ko not_active Abandoned
- 2016-04-12 JP JP2017553118A patent/JP6971850B2/ja active Active
- 2016-04-12 AU AU2016249981A patent/AU2016249981B2/en not_active Ceased
- 2016-04-12 CN CN202210198527.4A patent/CN114681608A/zh active Pending
- 2016-04-12 CN CN201680034138.0A patent/CN107709365A/zh active Pending
- 2016-04-12 TW TW105111397A patent/TWI725966B/zh active
- 2016-04-12 SI SI201631091T patent/SI3283527T1/sl unknown
- 2016-04-12 EP EP20212116.6A patent/EP3964527A3/en not_active Withdrawn
- 2016-04-12 PL PL16718802T patent/PL3283527T3/pl unknown
- 2016-04-12 BR BR112017020952A patent/BR112017020952A2/pt not_active IP Right Cessation
- 2016-04-12 WO PCT/US2016/027038 patent/WO2016168149A1/en not_active Ceased
- 2016-04-12 EP EP16718802.8A patent/EP3283527B1/en active Active
- 2016-04-12 RS RS20210272A patent/RS61531B1/sr unknown
- 2016-04-12 DK DK16718802.8T patent/DK3283527T3/da active
- 2016-04-12 US US15/564,866 patent/US20180085472A1/en not_active Abandoned
- 2016-04-12 MX MX2017013178A patent/MX388015B/es unknown
-
2017
- 2017-09-26 IL IL254705A patent/IL254705B/en unknown
-
2020
- 2020-02-10 US US16/786,158 patent/US11559583B2/en active Active
-
2021
- 2021-03-11 CY CY20211100207T patent/CY1123972T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512430A5 (enExample) | ||
| Salomon et al. | Next generation CD40 agonistic antibodies for cancer immunotherapy | |
| Martin-Liberal et al. | The expanding role of immunotherapy | |
| JP7382829B2 (ja) | キメラ抗原受容体を発現するｔ細胞 | |
| Croft et al. | Clinical targeting of the TNF and TNFR superfamilies | |
| ES2754557T3 (es) | Combinación de un anticuerpo CD30XCD16A con un anticuerpo antagonista anti-PD-1 para terapia | |
| JP2023126946A (ja) | 抗ｌａｇ－３抗体、ｐｄ－１経路阻害剤および免疫療法剤の組み合わせを含む組成物 | |
| Kim et al. | 4-1BB: A promising target for cancer immunotherapy | |
| AU2016269145B2 (en) | Therapeutic combinations and methods for treating neoplasia | |
| Yao et al. | Advances in targeting cell surface signalling molecules for immune modulation | |
| WO2016126781A4 (en) | Tnfrsf-binding agents and uses thereof | |
| US20210015870A1 (en) | Bcma-car-t cells | |
| JP2017533207A5 (enExample) | ||
| JP2023138960A (ja) | キメラ抗原受容体を発現する免疫細胞 | |
| WO2017197231A1 (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| JP2019528082A5 (enExample) | ||
| WO2019094574A1 (en) | Bispecific fusion polypeptides and methods of use thereof | |
| Patel et al. | Prominent targets for cancer care: immunotherapy perspective | |
| Han et al. | Stimulating T cells against cancer with agonist immunostimulatory monoclonal antibodies | |
| KR20200074214A (ko) | 암을 치료하는데 사용하기 위한 면역자극 효능작용 항체 | |
| JP7254710B2 (ja) | Ｃｄ３７を標的にするキメラ抗原受容体 | |
| Ababneh et al. | Tumor necrosis factor superfamily signaling: life and death in cancer | |
| JP2022535410A (ja) | Ｔａｃｉを標的とする抗体及びキメラ抗原受容体 | |
| BR112017028316A2 (en) | btla fusion protein agonists and uses thereof | |
| Ritu et al. | Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics |